chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient experienced chills; weakness; mild fever within 24 hrs from getting a second shot of vaccine; This is a spontaneous report from a contactable consumer. This unspecified age and gender consumer (Patient) reported that received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. On an unspecified date the patient experienced chills, weakness and mild fever within 24hours from getting a second shot of vaccine.  The patient had not took any further medications, the fever normalized within 12hours. The patient did not received any treatment for the adverse events. The outcome of events was unknown.  No follow-up attempts are possible. information about lot/batch number cannot be obtained.
patient came in on 12/6 saying he has been having a swollen arm where injection was given. the arm in his arm is a little swollen and hard. it is also warm to touch. he reports no pain moving the arm and has no fever or other symptoms.
Information has been received from a health care facility concerning a 12 month old white male with no known allergies or past medical history who on 14-JUL-2006 was vaccinated SC in the right upper leg with a first dose of Varivax (lot#651045/034R). There was no concomitant medication or illness at the time of vaccination. On 23-JUL-2006 the patient developed chickenpox. Medical attention was sought at an urgent care center. Subsequently, in July 2006, the patient recovered. Additional information is not expected.
Migraine headache which I typically don't experience. Teeth pain/ache, muscle aches Mentally fuzzy and overall experiencing mild lethargy. I'm able to continue with my day at work but would rather be resting.
Information has been received from a nurse concerning a 14 year old female who on 23-JAN-2007 was vaccinated with the first dose of GARDASIL vaccine (lot number not provided). The nurse reported that after the patient received the vaccination she turned pale "within 10 minutes of vaccination".  The nurse reported that the patient's blood pressure was 120/80 prior to vaccination and her blood pressure dropped to 90/50 about ten minutes after the patient was vaccinated. The nurse reported that the patient was sent to the Emergency Room (ER) at the hospital nearby for treatment and observation. Additional information has been requested. This is in follow-up to report (s) previously submitted on 2/14/2007. Initial and followup information has been received from a registered nurse concerning a 14 year old female who had finished menses and had heavey dysmenorrhea on 23-JAN-2007 was vaccinated IM in the left deltoid at 10:20 with her first dose of GARDASIL vaccine (Lot # 653918/0954F). Concomitant therapy included TOPRANIL. On 23-H+JAN_2007, at 10:30 the patient turned pale became dizzy and lightheaded after being vaccinated and her blood pressure fropped to 90/50 blood pressure prior to vaccination was 104/64. She was given fluids and something to eat and the dizziness did not improve. She was sent to the Emergency Room for evaluation. The ER report was normal. At the time of the report her blood pressure stayed under 100. No further informaion is available.
Patient received Infanrix DTap intended for ages 6 wks-7yrs instead of Tdap.
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose 12/21/21 2nd dose01/08/21 Diagnosed covid positive:08/19/21 Symptom onset:08/17/21 Exposure: Symptoms:sneezing.
Pt complained about onset of severe pain 4 hour from the time of vaccine administration. As per patient, she got hives and rash after 2 days. Rash remained even after 6 days. Patient also complained about itching. Patient has only allergy to penicillin. Patient required multiple doctor visits. MD does not believe symptoms were from the vaccine and reports as a co-incidence. Patient was treated with multiple creams such as clobetasol and clindamycin. Patient reports almost complete relief of symptoms as of 12/13/2013.
mild rash; This is a spontaneous report from a contactable consumer. A female patient of an unspecified age received bnt162b2 (BNT162B2, Solution for injection, lot number and expiry date not reported), via an unspecified route of administration in Dec2020 at a single dose for Covid-19 Vaccine. The patient's medical history and concomitant medications were not reported.  Patient just had her covid vaccine shot a week ago (Dec2020) and was experiencing mild rash. Patient was asking if she was contagious. The outcome of the event mild rash was unknown.    Lot/Batch and Expiration date has been requested.
This spontaneous prospective pregnancy case was reported by a health care professional and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy), PAIN IN EXTREMITY (sore arm) and FATIGUE (fatigue) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039A21A and 031A21A) for COVID-19 vaccination. No Medical History information was reported. On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on 15-Apr-2021 and the estimated date of delivery was 31-Dec-2021. On 16-Apr-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy), PAIN IN EXTREMITY (sore arm) and FATIGUE (fatigue). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) during pregnancy.  On 16-Apr-2021, MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy) had resolved. At the time of the report, PAIN IN EXTREMITY (sore arm) and FATIGUE (fatigue) outcome was unknown. Not Provided. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. Patient LMP date was 15-APR-2021. No concomitant medications were added. No treatment medications were added. Most recent FOLLOW-UP information incorporated above includes: On 21-Apr-2021: Internal review on 26-JUL-2021 resulted in Update of Reporter details, Prospective checked ,Birth type, Fetal outcome , vaccine facility type, country, expiration date ,event start date and end date, outcome of event .
10-06-07fever 103                              10-07-07 Rash for 5-6 days
Intense body pain; Diarrhea; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Intense body pain), DIARRHOEA (Diarrhea) and NAUSEA (Nausea) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 020B21A) for COVID-19 vaccination.     No medical history provided.     On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Mar-2021, the patient experienced PAIN (Intense body pain), DIARRHOEA (Diarrhea) and NAUSEA (Nausea). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, PAIN (Intense body pain), DIARRHOEA (Diarrhea) and NAUSEA (Nausea) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Bumps on abdomen - 4/14/21. Hives on thigh, swollen upper lip - morning of 4/20/2021. Injection site pain - right after vaccination, subsided next day. Covid-19 positive (PCR test verified), swollen lips, itchy hives on thighs half the size of a dime in clusters, bumps on abdomen (looks like little water blisters - burst and crust over; doesn't itch) - still occurring Per poison specialist - Wait 90 days to get 2nd dose. Contact PCP in regards to swollen lips, hives, and bumps. Can put hydrocortisone cream on to help with itching, but still consult with PCP. Inform PCP of Covid-19 positive test, will be best to remain in isolation and contact PCP over the phone first to limit the spread of Covid-19.
Had Td and HBV #2 on 11/4/02. Woke up on 11/5/02 with achy joints (especially knees and jaw). Starting running a temperature of 101.5 to 102 degrees then vomited his lunch at approx. noon on 11/5/02. Mother called report to PHN at 1:15pm and is giving Tylenol for achy joints and to control temperature.
5 minutes post vax, the pt developed hives in the right groin area and upper body with itching. Treated with Benadryl. The pt was observed for 15 minutes. Hives decreased and pt went home.
The nurse reported that a child was administered a Varivax vaccine that underwent a temperature excursion; This spontaneous report was received from a nurse referring to a child of unknown gender. The patient's medical history, historical drugs, concurrent conditions and concomitant medications were not provided    In October 2020, the patient was vaccinated with varicella virus vaccine live (oka/merck)(VARIVAX) 0.5 milliliter, lot number T002846 and expiration date of 23-JAN-2022 for prophylaxis (route of administration not provided) that had underwent a temperature excursion.    The reported stated that some varicella virus vaccine live (oka/merck)(VARIVAX) were put in the refrigerator instead of the freezer.  Besides the previously mentioned lot number, there was another one involved in the temperature excursion, S035124 with expiration date 04-NOV-2021. The temperature excursion occurred from 01-OCT-2020 at 4:30 pm to 02-OCT-2020 at 9:30 am, with a total time frame of 17 hours over 5 Fahrenheit degrees (F), and a highest temperature of 44.6 F. The vaccine had not had any prior temperature excursion. A total of 10 units of each lot were affected. The call was due to a digital data logger.
Nerve pain from (L) deltoid (injection site) to (L) wrist; uncomfortable, radiating pain downward.
I am 36 weeks pregnant. On the morning of September 28th, I called Pharmacy and asked if they had "the RSV vaccine that's now approved for pregnant women". I let them know I have a prescription from my OB's office offering their approval as well if they wanted to see that. They confirmed to me they would give me the RSV vaccine. In the afternoon, I entered the pharmacy, approached the front desk and said I was here for the RSV vaccine. During my interaction with the woman at the desk, I asked "This is the Pfizer shot, right - Abrysvo?" Her reply was "Yes, this is the RSV vaccine." Based on that interaction, I took that as verbal confirmation that I was to receive the Abrysvo vaccine that has been approved by FDA/CDC for administration to pregnant women. A little later, I was brought into the pharmacist's office, asked which arm I wanted to use, and was quickly injected with a vaccine. After the vaccine was administered I saw the box it came in on the pharmacist's desk. The box said "Arexvy". I asked "Did you just give me Arexvy, not the Pfizer Abrysvo shot that's approved for pregnant women?" The pharmacist replied to confirm that yes, he administered me Arexvy. I said "That's not approved for pregnant women!" The pharmacist  replied that my prescription had not specified which RSV vaccine brand to use, so he thought it was okay to give me Arexvy. I took a picture of the box and then left.
Mom called today 8/10/11 at 3:28 PM stating that patient c/o left eye watering and (L) side of mouth cannot smile. Told mom to come to office to be evaluated. Mom called again at 4:08 PM  stating that she prefer to go hospital. She then states that (L) eye watering happens 40 hrs after the vaccines given.
4 minutes after the vaccine I had difficulty swallowing and numbness and tingling in my lips. The difficulty swallowing lasted approximately 2 minutes and the numbness/tingling lasted about 20 minutes. Both self resolved.
PT UNDER AGE OF 18 ORDER FROM MD TO GIVE DUE TO HX OF ALLERGIES
1115 immediately c/o light headedness and tingling of both hands. Became semi responsive. BP 70/50, O2 applied, clammy and pale. 1135 was to walk across hall to lay down. More alert and responsive. BP 104/70.
I am not functioning well at all; This is a spontaneous report from a contactable consumer (patient).  A patient of unspecified age and gender received bnt162b2 (BNT162B2, Pfizer-BioNTech Covid-19 mRNA Vaccine, Solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date patient experienced i am not functioning well at all. I went to the Doctor like 5 times they cannot find anything wrong it is all because I have to get the second vaccine. Consumer was informed about Pfizer Medical Information Department. As consumer abruptly hung up the call. Product details, Pharmacy details and further probing could not be done. Limited information available over the call and appropriate response could not be provided. The outcome of event was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Patient presented to the vaccination site on 11/02/21. The client notified RN that he received a complete series of Sputnik first dose was given on 6/18/21 and second dose was given on 7/17/21 COVID vaccine. RN submitted a medical consult via text message to Leads, requesting to proceed with the COVID vaccine (Janssen). Per CDC guidance, approval to proceed with COVID vaccine (Janssen) was obtained from medical consult team via text message from (RN), Lead . Client received COVID vaccine (Janssen) Lot#1855194 on 11/02/21. The client did not report any symptoms during the 30 minute observation period. RN educated client on possible adverse reactions and when to seek medical care. The client left the vaccination site unassisted and with a steady gait at 1220.
Information has been received from an office staff member concerning a female adult patient who on 11-OCT-2006 was vaccinated with a first dose of Pneumovax 23 (0.5 ml) (lot # 651400/0618F), intramuscularly. Concomitant therapy included influenza virus vaccine (unspecified). Subsequently, the patient developed edema, redness and warmth at the injection site. At the time of the report, the patient was considered to be recovering. Additional information has been requested.
Given H1N1 on 11-13-09. Developed hives 11-15-09. Seen in ER-T-101 degrees. To MD on 11-16. Full body rash. T-102? 11-17-developed a cough, cyanosis, hands, feet & torso. Returned to ED. Transferred to another hospital.12/2/2009 MR, DC summary for 11/18/2009. Patient with c/o's increasing fever and maculopapular rash and seen in another hospital ED on 11/15/2009 and dx'd with Acute otitis media, tx'd with Azithromycin which worsened the rash and caused periorbital edema. Patient went to PCP and dx'd with erythema multiform and given Benadryl. Brought to ED on 11/18/2009 when edema increased and noted purplish discoloration, Tx: IVF, IV Solumedrol, Benadryl. DX Stevens Johnson syndrome.
Arm soreness at injection site. Started approx 4 hours after injection. Much worse upon waking. Fatigue started next day upon awakening, but got much worse about 19 hours later. Soreness started feeling better 24 hours later, but exhaustion continues.
Vaccines given on 1/31/03; fever low grade after vaccines. Seen in ER on 2/8/03 because of status epilepticus. Medical Records received on 4/23/2003 states fussiness.
TOOK ALL FOUR DOSES AT ONCE; A spontaneous case report was received from a nurse on 28-Feb-2019 for two consumers.  Based on the information obtained from the nurse, two individual case safety reports PVX201903-000162 (PVX2019-551; younger female) and PVX201903-000163 (PVX2019-552, elder female) were created and cross-linked in the database.  This case report describes a 44-year-female consumer who "took all four doses at once". The consumer was receiving Vivotif for an unknown indication.  It was reported that the consumer took all the four doses of Vivotif on 08-Feb-2019.  The action taken with Vivotif with respect to event "took all four doses at once" was not applicable.  The clinical outcome of the event "took all four doses at once" was unknown.  Company's Comment: The causality of the event "took all four doses at once" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event "took all four doses at once" was considered as not applicable. US-PaxVax Berna GmbH-PVX201903-000163:
This spontaneous report was received from an office manager and refers to a 19 months old patient of unknown gender. There was no information about patient's concomitant medications and pertinent medical history reported. On 01-DEC-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with expiration date 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.; Sender's Comments:  US-009507513-1612USA007652: US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004468: US-009507513-1704USA004469: US-009507513-1704USA004470: US-009507513-1704USA004471: US-009507513-1704USA004472: US-009507513-1704USA004473: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004494: US-009507513-1704USA004495: US-009507513-1704USA004496: US-009507513-1704USA004497: US-009507513-1704USA004498: US-009507513-1704USA004499: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509: US-009507513-1704USA004510: US-009507513-1704USA004511: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515: US-009507513-1704USA004516: US-009507513-1704USA004517:
This spontaneous report was received from a physician refers to a 18 year old male patient. The patient had penicillin allergy and allergy to a lot of other unspecified drugs. On unknown dates the patient was vaccinated with the first and second doses of M-M-R II (strength, route, lot number and expiry dates were not reported). There were no concomitant medications reported. It was reported that the patient had received the first dose of M-M-R II too early, when he was not even 4 months old (date unspecified). A lab test was carried out for titers for measles, mumps and rubella vaccine on an unknown date and the patient showed low titers for measles component. The patient did not receive any treatment for the event. The patient had sought medical attention by doctor visit. There was no product quality complaint involved. The outcome of low titers for measles component was reported as not recovered at the time of the report. The causality of the event low titers for measles component was unknown. Additional information has been requested.
This spontaneous report was received from a health care professional refers to unspecified number of unspecified patients of unknown demographics. Approximately in 2016 (also reported as "unspecified dates starting on or after 23-FEB-2016"} the patients were vaccinated with improperly stored RECOMBIVAX HB (dosing regimen unspecified) (lot L027733, expiry 13-SEP-2017; lot L033343, expiry 13-SEP-2017; lot L044694, expiry 04-FEB-2018). Excursion details are as follows: which were exposed to the following conditions, were administered to unspecified patients: temperature:1C, Time frame: 23 hours, there was no previous temperature excursion. It was a call because of the data logger. No adverse effect reported. GARDASIL and M-M-R II appear in the product list as these products were involved in the excursion, however, no improperly stored doses of GARDASIL or M-M-R II were administered. No additional information was provided. This is one of the two reports from the same reporter. Additional information has been requested.
On April 4, 2008, patient received her 12 month vaccines.  On April 24 the patient presented with discrete papular rash on legs.  She had just eaten some eggs for breakfast.  Mom wondered if rash was due to eggs or MMR/varicella.  T-97, wt-8kg.  No other symptoms.  Rash improved that night without therapy.  Presented 4-25 with generalized urticaria, (-) wheezing, (-) swelling.  Given Benadryl.
Sinus infection; This spontaneous case was reported by a consumer and describes the occurrence of SINUSITIS (Sinus infection) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SINUSITIS (Sinus infection) (seriousness criterion medically significant). At the time of the report, SINUSITIS (Sinus infection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Hello Dr., I got my second vaccination on 12-8-2021. The evening of 12-8, I had general malaise. 12-9, I had persistent body aches, slight headache, malaise, my left lymph node was swollen, one palpable nodule, less than the size of a dime, at the injection site, and another palpable nodule about 7 cms below that, size of a quarter or half dollar, slight pain at the injection site, and in the evening, I believe the lymph node in my left armpit was sore, but when palpating, I felt nothing, and no pain. 12-10, so far I'm feeling better than I did, slight headache on and off, general malaise, nodules on my arm are less tender and getting softer. Still a pain in my armpit. General feeling of coming down with a cold.
High fever reaching 103 degrees and severe nausea. Treated fever with extra strength tylenol and nausea with prescription of Zofran. Nausea symptoms mitigated after second dose of Zofran taken evening of 4/29. Fever broke evening of 4/30.
WRONG DOB ENTERED BY PARENT ON VACCINE CONSENT. PATIENT RECEIVED WRONG PFIZER FORMULATION FOR AGE GROUP. CHILD WAS 4YO AT TIME OF VACCINATION AND RECEIVED THE ORANGE CAP  5-11YO FORMULATION INSTEAD OF THE 6M-4YO MAROON CAP.